Cancer Immunotherapy Market & Clinical Pipeline Insight
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
With more than 6 million deaths worldwide in 2013, cancer has become one of the most pressing health problems faced by almost all the economies of the world. Inspite of the fact that there have been significant improvisation and advancements in surgery, radiation therapy, and chemotherapy over the years, there has hardly been any significant control of this disease by these treatments. There have been many developments in the recent past, in terms of introducing novel methods of treatment of cancer, which are likely to have a great potential. Cancer immunotherapy is one such development in the field of cancer treatment. This treatment option involves manipulating the human body’s immune system in order to target the cancer.
The recent years have witnessed the emergence of cancer immunotherapy, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past 15-20 years, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period. Cancer immunotherapy has been made commercial and the market availability of the agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body’s immune system.
There has been some extensive research in the previous decade which has led to the development of vital novel therapies for diseases such as bladder cancer, renal cell carcinoma, colon cancer, and some leukemias. Additionally, these significant achievements in cancer immunotherapy have been popular on similar lines as improved techniques such as genetic engineering and monoclonal antibody generation. Thus, both these set of advancements have been working hand-in-hand to bring the cancer immunotherapy on the growth trajectory. The future is also likely to witness a continued close association between these two fields of advancements.
Cancer immunotherapy will continue to be overflowing with huge potential as a result of an increasing number of new discoveries and techniques. Inspite of advances being made in terms of understanding of the complexities of the human immune system, as compared to the state of immunology during Dr. Coley, there is still significant work which needs to be done. The complete detailed understanding is yet to be deciphered, which is one of the major reasons for cancer immunotherapy not being in widespread use.
“Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:
With more than 6 million deaths worldwide in 2013, cancer has become one of the most pressing health problems faced by almost all the economies of the world. Inspite of the fact that there have been significant improvisation and advancements in surgery, radiation therapy, and chemotherapy over the years, there has hardly been any significant control of this disease by these treatments. There have been many developments in the recent past, in terms of introducing novel methods of treatment of cancer, which are likely to have a great potential. Cancer immunotherapy is one such development in the field of cancer treatment. This treatment option involves manipulating the human body’s immune system in order to target the cancer.
The recent years have witnessed the emergence of cancer immunotherapy, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past 15-20 years, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period. Cancer immunotherapy has been made commercial and the market availability of the agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body’s immune system.
There has been some extensive research in the previous decade which has led to the development of vital novel therapies for diseases such as bladder cancer, renal cell carcinoma, colon cancer, and some leukemias. Additionally, these significant achievements in cancer immunotherapy have been popular on similar lines as improved techniques such as genetic engineering and monoclonal antibody generation. Thus, both these set of advancements have been working hand-in-hand to bring the cancer immunotherapy on the growth trajectory. The future is also likely to witness a continued close association between these two fields of advancements.
Cancer immunotherapy will continue to be overflowing with huge potential as a result of an increasing number of new discoveries and techniques. Inspite of advances being made in terms of understanding of the complexities of the human immune system, as compared to the state of immunology during Dr. Coley, there is still significant work which needs to be done. The complete detailed understanding is yet to be deciphered, which is one of the major reasons for cancer immunotherapy not being in widespread use.
“Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:
- Cancer Immunotherapy Market Overview
- Cancer Immunotherapy Market Dynamics
- Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
- Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
- Cancer Vaccine Clinical Pipeline by Phase & Country
- Oncolytic Viruses Clinical Pipeline by Phase & Country
- Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
- Cancer Cell Therapy Clinical Trial Insight by Phase & Country
- Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical Pipeline
1. INTRODUCTION TO CANCER IMMUNOTHERAPY (PAGE 6)
2. MECHANISM OF CANCER IMMUNOTHERAPY (PAGE 11)
2.1 Genetic engineering
2.2 Hybridoma Technology
2.3 Humanization of Monoclonal Antibodies
2.4 Overcoming the HAMA Response via Modern Technology
3. TYPES OF CANCER IMMUNOTHERAPY (PAGE 14)
3.1 Monoclonal Antibodies
3.2 Checkpoint Inhibitors
3.3 Vaccination
3.4 Non Specific Immunotherapies
4. WHY NEED FOR CANCER IMMUNOTHERAPY (PAGE 23)
5. GLOBAL CANCER IMMUNOTHERAPY MARKET OVERVIEW (PAGE 26)
6. CANCER IMMUNOTHERAPY MARKET DYNAMICS (PAGE 33)
6.1 Favorable Market Drivers
6.2 Key issues to be Discussed
6.3 Future of Cancer Immunotherapy
7. CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY PHASE & COUNTRY (PAGE 41)
7.1 Clinical Pipeline Overview
7.2 Clinical Pipeline Insight: Research till Registration
7.3 Marketed Cancer Monoclonal Antibodies
8. CANCER VACCINE CLINICAL PIPELINE BY PHASE & COUNTRY (PAGE 1088)
8.1 Clinical Pipeline Overview
8.2 Clinical Pipeline Insight: Research till Registration
8.3 Marketed Cancer Vaccines
9. ONCOLYTIC VIRUSES CLINICAL PIPELINE BY PHASE & COUNTRY (PAGE 1640)
9.1 Clinical Pipeline Overview
9.2 Clinical Pipeline insight: Research till Registration
10. CANCER CYTOKINE THERAPY CLINICAL TRIAL INSIGHT BY PHASE & COUNTRY (PAGE 1714)
10.1 Clinical Pipeline Overview
10.2 Clinical Pipeline Insight: Research till Preregistration
10.3 Marketed Cancer Cytokines Threapy
11. CANCER CELL THERAPY CLINICAL TRIAL INSIGHT BY PHASE & COUNTRY (PAGE 1844)
11.1 Clinical Pipeline Overview
11.2 Clinical Pipeline Insight: Research till Preregistration
11.3 Marketed Cancer Cell Therapy
12. COMPETITIVE LANDSCAPE: BUSINESS OVERVIEW & PRODUCT PIPELINE (PAGE 1977)
12.1 Advaxis
12.2 Celldex Therapeutics
12.3 Dendreon Corporation
12.4 Galena Biopharma
12.5 ImmunoCellular Therapeutics
12.6 ImmunoGen
12.7 Inovio Pharmaceuticals
12.8 Merck
12.9 NeoStem Oncology
12.10 NewLink Genetics
12.11 Northwest Biotherapeutics
12.12 Novartis
12.13 Peregrine Pharmaceuticals
12.14 Roche
12.15 Seattle Genetics
2. MECHANISM OF CANCER IMMUNOTHERAPY (PAGE 11)
2.1 Genetic engineering
2.2 Hybridoma Technology
2.3 Humanization of Monoclonal Antibodies
2.4 Overcoming the HAMA Response via Modern Technology
3. TYPES OF CANCER IMMUNOTHERAPY (PAGE 14)
3.1 Monoclonal Antibodies
3.2 Checkpoint Inhibitors
3.3 Vaccination
3.4 Non Specific Immunotherapies
4. WHY NEED FOR CANCER IMMUNOTHERAPY (PAGE 23)
5. GLOBAL CANCER IMMUNOTHERAPY MARKET OVERVIEW (PAGE 26)
6. CANCER IMMUNOTHERAPY MARKET DYNAMICS (PAGE 33)
6.1 Favorable Market Drivers
6.2 Key issues to be Discussed
6.3 Future of Cancer Immunotherapy
7. CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY PHASE & COUNTRY (PAGE 41)
7.1 Clinical Pipeline Overview
7.2 Clinical Pipeline Insight: Research till Registration
7.3 Marketed Cancer Monoclonal Antibodies
8. CANCER VACCINE CLINICAL PIPELINE BY PHASE & COUNTRY (PAGE 1088)
8.1 Clinical Pipeline Overview
8.2 Clinical Pipeline Insight: Research till Registration
8.3 Marketed Cancer Vaccines
9. ONCOLYTIC VIRUSES CLINICAL PIPELINE BY PHASE & COUNTRY (PAGE 1640)
9.1 Clinical Pipeline Overview
9.2 Clinical Pipeline insight: Research till Registration
10. CANCER CYTOKINE THERAPY CLINICAL TRIAL INSIGHT BY PHASE & COUNTRY (PAGE 1714)
10.1 Clinical Pipeline Overview
10.2 Clinical Pipeline Insight: Research till Preregistration
10.3 Marketed Cancer Cytokines Threapy
11. CANCER CELL THERAPY CLINICAL TRIAL INSIGHT BY PHASE & COUNTRY (PAGE 1844)
11.1 Clinical Pipeline Overview
11.2 Clinical Pipeline Insight: Research till Preregistration
11.3 Marketed Cancer Cell Therapy
12. COMPETITIVE LANDSCAPE: BUSINESS OVERVIEW & PRODUCT PIPELINE (PAGE 1977)
12.1 Advaxis
12.2 Celldex Therapeutics
12.3 Dendreon Corporation
12.4 Galena Biopharma
12.5 ImmunoCellular Therapeutics
12.6 ImmunoGen
12.7 Inovio Pharmaceuticals
12.8 Merck
12.9 NeoStem Oncology
12.10 NewLink Genetics
12.11 Northwest Biotherapeutics
12.12 Novartis
12.13 Peregrine Pharmaceuticals
12.14 Roche
12.15 Seattle Genetics
LIST OF FIGURES
Figure 1-1: Introduction to Cancer Therapies
Figure 1-2: Key Events in the History of Cancer Immunotherapy
Figure 2-1: Mechanism of Cancer Immunotherapy
Figure 3-1: Type of Cancer Immunotherapy
Figure 5-1: Cancer Immunotherapy Market Category
Figure 5-2: Cancer Immunotherapy Market (US$ Billion), 2014-2020
Figure 5-3: Cancer Immunotherapy Market by Region (%), 2014 & 2020
Figure 5-4: Regulatory Milestones for Cancer Immunotherapy
Figure 7-1: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2014
Figure 7-2: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2014
Figure 8-1: Cancer Vaccine Clinical Pipeline by Phase (%), 2014
Figure 8-2: Cancer Vaccine Clinical Pipeline by Phase (Number), 2014
Figure 9-1: Oncolytic Viruses Clinical Pipeline by Phase (%), 2014
Figure 9-2: Oncolytic Viruses Clinical Pipeline by Phase (Number), 2014
Figure 10-1: Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
Figure 10-2: Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
Figure 11-1: Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
Figure 11-2: Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
Figure 12-1: Advaxis Clinical Pipeline
Figure 12-2: Celldex Therapeutics Clinical Pipeline
Figure 12-3: Galena Biopharma Clinical Pipeline
Figure 12-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 12-5: ImmunoGen Clinical Pipeline
Figure 12-6: Inovio Pharmaceuticals Clinical Pipeline
Figure 12-7: NewLink Genetics Corporation Clinical Pipeline
Figure 12-8: Northwest Biotherapeutics Clinical Pipeline
Figure 12-9: Peregrine Pharmaceuticals Clinical Pipeline
Figure 12-10: Seattle Genetics Clinical Pipeline
Figure 1-1: Introduction to Cancer Therapies
Figure 1-2: Key Events in the History of Cancer Immunotherapy
Figure 2-1: Mechanism of Cancer Immunotherapy
Figure 3-1: Type of Cancer Immunotherapy
Figure 5-1: Cancer Immunotherapy Market Category
Figure 5-2: Cancer Immunotherapy Market (US$ Billion), 2014-2020
Figure 5-3: Cancer Immunotherapy Market by Region (%), 2014 & 2020
Figure 5-4: Regulatory Milestones for Cancer Immunotherapy
Figure 7-1: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2014
Figure 7-2: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2014
Figure 8-1: Cancer Vaccine Clinical Pipeline by Phase (%), 2014
Figure 8-2: Cancer Vaccine Clinical Pipeline by Phase (Number), 2014
Figure 9-1: Oncolytic Viruses Clinical Pipeline by Phase (%), 2014
Figure 9-2: Oncolytic Viruses Clinical Pipeline by Phase (Number), 2014
Figure 10-1: Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
Figure 10-2: Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
Figure 11-1: Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
Figure 11-2: Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
Figure 12-1: Advaxis Clinical Pipeline
Figure 12-2: Celldex Therapeutics Clinical Pipeline
Figure 12-3: Galena Biopharma Clinical Pipeline
Figure 12-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 12-5: ImmunoGen Clinical Pipeline
Figure 12-6: Inovio Pharmaceuticals Clinical Pipeline
Figure 12-7: NewLink Genetics Corporation Clinical Pipeline
Figure 12-8: Northwest Biotherapeutics Clinical Pipeline
Figure 12-9: Peregrine Pharmaceuticals Clinical Pipeline
Figure 12-10: Seattle Genetics Clinical Pipeline
